All In MedTech

Device Trial Radar · NCT02614768

Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Jul 2015

Primary completion

Aug 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Medical University of GrazAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess accuracy and reliability of the SPIDIMAN continuous glucose monitoring (CGM) sensor system with regard to values as measured by Super GL and compare these results with similar evaluations of the Medtronic MiniMed 640G system, the Abbott FreeStyle Libre Flash Sensor and the DexCom G4 Platinum Sensor in patients with type 1 Diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Glucose SensorDevice

    The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled "for investigative use only".

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15%Time frame: 36 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.